Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
May 26 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the William Blair 42nd Annual Growth Stock Conference, which takes
place June 6-9, 2022, in Chicago at the Loews Chicago Hotel. Ron
Rocca, Exagen’s President and Chief Executive Officer, and Kamal
Adawi, Exagen’s Chief Financial Officer, will present on Thursday,
June 9th, at 12:40 PM CT. Interested parties may access the webcast
of the presentation using a link on Exagen’s website at
https://investors.exagen.com/events.
About Exagen Inc.
Exagen (Nasdaq: XGN) is a leading provider of autoimmune
diagnostic, prognostic, and monitoring testing solutions.
Exagen is a patient focused, discovery driven organization built on
the success of AVISE testing and is investing in its product
pipeline to support patients throughout their autoimmune diagnosis
and treatment. Exagen’s goal is to assist patients, physicians, and
payors by enabling precision medicine. Exagen is located in San
Diego County with clinical and research and development
laboratories in Vista, CA.
For more information, please visit Exagen.com and follow
@ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen's
current beliefs and expectations. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: the COVID-19 pandemic may continue to adversely affect
its business, financial condition and results of operations,
including as a result of slowdown in its operations as well as
those of its suppliers and courier services, impeding patient
movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for its tests causing an increase in cost per test,
its sales and commercialization activities and its ability to
receive specimens and perform or deliver the results from its
tests, delays in reimbursement and coverage decisions from Medicare
and third-party payors and in interactions with regulatory
authorities, and delays in ongoing and planned clinical trials
involving its tests; Exagen’s commercial success depends upon
attaining and maintaining significant market acceptance of its
testing products and promoted therapeutics among rheumatologists,
patients, third-party payors and others in the medical community;
Exagen’s ability to successfully execute on its business
strategies; third-party payors not providing coverage and adequate
reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen’s ability to collect funds due;
expectations regarding its pipeline products, including the
development of the AVISE RADR platform; Exagen’s ability to obtain
and maintain intellectual property protection for its testing
products; regulatory developments affecting Exagen’s business; and
other risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange Commission (“SEC”),
including under the heading “Risk Factors” in Exagen’s Annual
Report on Form 10-K for the year ended December 31, 2021 and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and Exagen undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024